Associate Professor, Medicine, Indiana University School of Medicine
Oncology
Dr. Daniela E. Matei, MD
|
|
Give Review
Daniela E. Matei practices Oncology. Daniela Matei is also published. She has 56 publications published. The lastest publication: "Preclinical and clinical evaluation of 5-fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with colorectal carcinoma.' She accepts Medicare payments and is registered with Medicare.gov.
Publications
- P1.08A phase 1 study of 3 different schedules of the folic acid-tubulysin small-molecule drug conjugate EC1456 in pts with advanced solid Tumors.
- Circulating tumor cell detection using a parallel flow micro-aperture chip system.
- High-Dose Chemotherapy for Recurrent Ovarian Germ Cell Tumors.
- An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer.
- TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian Cancer cells.
- The novel, small molecule DNA methylation inhibitor SGI-110 as an ovarian Cancer chemosensitizer.
- Epigenetic Targeting of Ovarian Cancer Stem Cells.
- β-Catenin-regulated ALDH1A1 is a target in ovarian Cancer spheroids.
- Decitabine reactivated pathways in platinum resistant ovarian Cancer.
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective Analysis of outcomes by BRCA status in a ra...
- Adjuvant therapy for endometrial Cancer.
- Endoglin for targeted Cancer treatment.
- Epithelial ovarian Cancer experimental models.
- Tissue transglutaminase regulates β-catenin signaling through a c-Src-dependent mechanism.
- Live tissue viability and chemosensitivity assays using digital holographic motility contrast imaging.
- ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian Cancer.
- Targeting the Insulin Growth Factor and the Vascular Endothelial Growth Factor Pathways in Ovarian Cancer.
- Targeting angiogenesis in ovarian Cancer.
- Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian Cancer.
- A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian Cancer.
- Epigenetic therapies for chemoresensitization of epithelial ovarian Cancer.
- Minireview: epigenetic changes in ovarian Cancer.
- A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent Ovarian carcinoma.
- Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian Cancer.
- Role of epigenomics in ovarian and endometrial Cancers.
- Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian Cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.
- Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian Cancer and primary peritoneal carcinomatosis : ...
- Sorafenib in combination with weekly topotecan in recurrent ovarian Cancer, a phase I/II study of the Hoosier Oncology Group.
- Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-Analysis.
- Activity of sorafenib in recurrent ovarian Cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
- Tissue transglutaminase protects epithelial ovarian Cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.
- Imatinib mesylate (Gleevec) inhibits ovarian Cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
- Epithelial-to-mesenchymal transition and Ovarian tumor progression induced by tissue transglutaminase.
- Identification and characterization of ovarian Cancer-initiating cells from primary human tumors.
- Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal Cancer: a gynecologic onco...
- Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refracto...
- Novel agents in ovarian Cancer.
- Enhanced peritoneal Ovarian tumor dissemination by tissue transglutaminase.
- Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study.
- PDGF BB induces VEGF secretion in ovarian Cancer.
- Autocrine activation of PDGFRalpha promotes the progression of ovarian Cancer.
- Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian Cancer: potential predictive relationship with tumor HER2 activation st...
- PDGF induced microRNA alterations in Cancer cells.
- Targeting Ovarian tumor cell adhesion mediated by tissue transglutaminase.
- Breast mass in a patient with ovarian Cancer: a case report.
- The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in Cancer cells.
- Actual 5-year survival of patients with stage IIIB Breast carcinoma: phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid.
- Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian Cancer by modulating cAMP-response element-binding protein activity.
- Blockade of FGF signaling: therapeutic promise for ovarian Cancer.
- Preclinical and clinical evaluation of 5-fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with coloRectal carcinoma.
- Periostin secreted by epithelial Ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility.
- Updates in the Management of Ovarian Germ Cell Tumors.
- Global DNA methylation profiling technologies and the ovarian Cancer methylome.
- Small molecule inhibitors target the tissue transglutaminase and fibronectin interaction.
- Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Schools
Faculty Of Medicine Bucharest University
SUNY Stony Brook
Procedures Preformed
- Thoracentesis
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
UCLA Medical Center -
SUNY Stony Brook University Hospital & Medical Center -
Carol Davila University of Medicine and Pharmacy
Drug Facts
| NPI NUMBER | 1558327486 | |
| NPPES Provider LastName | MATEI | |
| NPPES Provider FirstName | DANIELA | |
| NPPES Provider ZIPCode | 462025112 | |
| NPPES Provider State | IN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 339.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 17.0 | |
| Percent Opioid Claims | 5.01 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1558327486 |
| Last Name Of The Provider | MATEI |
| First Name Of The Provider | DANIELA |
| View All |
Similar Doctors
|
|
Dr. Naveen Manchanda, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Niraj Gupta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Asok C. Antony, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tandra Anand, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. El-Sayed M. Aly, MD |
|
|
Dr. Anise T. Burki, MD |
|
|
Dr. Erin V. Newton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sead Beganovic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elena G. Chiorean, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lanting Liu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Travis J. Osterman, DO |
|
|
Dr. Robert L. Ilaria, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rajesh V. Shah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Maitri Kalra, MB BS
This Doctor is OpenDoctor Recommended.
|